PE = 32 less than Industry PE PBV also less than Industry PBV PEG = 2.4 Low ROE, ROCE Good sales and profit growth in last 5 years. Last 1 year sales and profit growth are excellent - 48% sales growth, 83% profit growth Stable promoter holding
Trade active
Less than ideal quarterly results
Mar 2024 BIOCON QOQ 👉Revenue drops -0.94% to 3917cr 👉Profit drops -70.39% to 223cr 👉EPS drops -79.45% to 1.13 👉EBITDA rose 1.11% to 913 👉EBITDA Margin drops 0.00% BPS to 23% YOY 👉Revenue rose 3.79% from 3774cr 👉Profit drops -46.14% from 414cr 👉EPS drops -56.70% from 2.61 👉EBITDA drops -4.60% from 957 👉EBITDA Margin drops -2.00% BPS from 25% Fundamentals 👉Stock Price is 269.7( as of 3/31/2024) 👉Stock PE is 31.65 👉Stock EPS is 8.52 👉Dividend Announced of Rs.0.5 Growth 👉2 Year Revenue CAGR is 34.28% 👉2 Year Profit CAGR is 29.67% 👉2 Year EPS CAGR is 25.61% 👉2 Year Price CAGR is -11.18%"
However at end of year, compared to last year. company has increased revenue nearly by a quarter and profits have nearly doubled. Margins remain mostly same and promoter holding is stable. Continue to stay invested
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.